Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 141 to 150 of 1514 total matches.
Pegaspargase for Acute Lymphoblastic Leukemia
The Medical Letter on Drugs and Therapeutics • Mar 17, 1995 (Issue 944)
, coagulopathy and hepatic
The Medical Letter, Vol. 37 (Issue 944) March 17, 1995, pp. 23-24
Copyright ...
Pegaspargase (peg as par jase; PEG-L-asparaginase; Oncaspar - Rh ne-Poulenc Rorer), a polyethylene glycol (PEG) conjugate of L-asparaginase, has been approved by the US Food and Drug Administration for treatment of acute lymphoblastic leukemia (ALL), the most common malignancy of childhood. The new drug is recommended only for patients who have had allergic reactions to asparaginase. Asparaginase is available commercially as Elspar, which is derived from Escherichia coli. A formulation derived from Erwinia chrysanthemi is available on an investigational basis (Ogden Bioservices,...
Abciximab to Prevent Vessel Closure After Angioplasty
The Medical Letter on Drugs and Therapeutics • Jun 09, 1995 (Issue 950)
stroke, it was associated with a two-fold increase
The Medical Letter, Vol. 37 (Issue 950) June 9, 1995 ...
Abciximab (ab sik si mab; ReoPro - Centocor), the Fab (fragment antigen binding) fragment of the chimeric human-murine monoclonal antibody 7E3 (c7E3 Fab), has been approved by the US Food and Drug Administration as an adjunct to percutaneous transluminal coronary angioplasty or atherectomy (PTCA) to prevent abrupt closure of the treated coronary vessel.
Dexrazoxane for Cardiac Protection Against Doxorubicin
The Medical Letter on Drugs and Therapeutics • Nov 24, 1995 (Issue 962)
cancer.
The Medical Letter, Vol. 37 (Issue 962) November 24, 1995, pp. 110-111
Copyright The Medical ...
Dexrazoxane (Zinecard - Pharmacia) was recently approved by the US Food and Drug Administration (FDA) for protection against cardiac toxicity from (Adriamycin, and others) in women with metastatic breast cancer.
Epoprostenol for Primary Pulmonary Hypertension
The Medical Letter on Drugs and Therapeutics • Feb 16, 1996 (Issue 968)
eventually require 200 ng/kg/min or
more.
The Medical Letter, Vol. 38 (Issue 968) February 16, 1996, pp. 14 ...
Epoprostenol sodium (Flolan - Glaxo Wellcome), also known as prostacyclin, has been approved by the US Food and Drug Administration for continuous intravenous treatment of primary pulmonary hypertension.
Ibutilide
The Medical Letter on Drugs and Therapeutics • Apr 12, 1996 (Issue 972)
) and astemizole (Hismanal), should be avoided.
The Medical Letter, Vol. 38 (Issue 972) April 12, 1996, p. 38 ...
Ibutilide fumarate (Corvert - Pharmacia & Upjohn), a new antiarrhythmic drug for intravenous use, has been approved by the US Food and Drug Administration for acute termination of atrial fibrillation or flutter of recent onset.
Azelaic Acid - A New Topical Drug for Acne
The Medical Letter on Drugs and Therapeutics • Jun 07, 1996 (Issue 976)
recommends using it cautiously in acne patients with dark complexions.
The Medical Letter, Vol. 38 (Issue ...
Azelaic acid, a naturally occurring heptanedicarboxylic acid, has been marketed in the USA as a 20% cream (Azelex - Allergan) for treatment of acne. The drug has been available in Europe for several years.
Bicalutamide for Prostate Cancer
The Medical Letter on Drugs and Therapeutics • Jun 21, 1996 (Issue 977)
flushes and increased aminotransferase activity can occur. Diarrhea
The Medical Letter, Vol. 38 (Issue ...
Bicalutamide (Casodex - Zeneca), an oral nonsteroidal antiandrogen similar to flutamide (Eulexin - Medical Letter, 31:72, 1989), is now available in the USA for treat-ment of advanced prostate cancer. The drug is recommended by the manufacturer for use concurrently with an analog of luteinizing hormone-releasing hormone (LHRH) such as leuprolide (Lupron; Lupron Depot) or goserelin (Zoladex -Medical Letter, 32:102, 1990).
Simethicone for Gastrointestinal gas
The Medical Letter on Drugs and Therapeutics • Jun 21, 1996 (Issue 977)
motility. One study in 290 women after a cesarean section
The Medical Letter, Vol. 38 (Issue 977) June 21 ...
Gastrointestinal gas may cause symptoms when excessive amounts become trapped in the stomach and intestinal tract. Simethicone (Gas-X, Maalox Anti-Gas, Mylanta Gas Relief, Mylicon, Phazyme), sold over-the-counter in capsules, tablets and infant drop formulations, is being heavily advertised to the public for symptomatic treatment of flatulence and gastric bloating. According to a recent press release, 'Phazyme works fast so people can continue living active lives and eating the foods they love without fear of embarrassment.' Products that combine one or more antacids with simethicone...
Interferon Beta-1a for Relapsing Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Jul 19, 1996 (Issue 979)
, 1995).
The Medical Letter, Vol. 38 (Issue 979) July 19, 1996, pp. 63-64
Copyright The Medical ...
Interferon β-1a (Avonex - Biogen), a recombinant form of human interferon β, has been approved by the US Food and Drug Administration (FDA) for treatment of relapsing forms of multiple sclerosis (MS). Interferon β-1a (Betaseron - Berlex), a recombinant analog of interferon β that differs from interferon β-1a in having a serine substituted for a cysteine and in not being glycosylated, was previously approved for this indication (Medical Letter, 35:61, 1993; BW van Oosten et al, Drugs, 49:200, 1995).
Bone Densitometry
The Medical Letter on Drugs and Therapeutics • Nov 22, 1996 (Issue 988)
, 1996).
The Medical Letter, Vol. 38 (Issue 988) November 22, 1996, pp. 103-104
Copyright The Medical ...
Use of alendronate (Fosamax), estrogen and other drugs for prevention and treatment of osteoporosis (Medical Letter, 38:1, 1996) has been accompanied by widespread availability of bone density screening tests, not only in doctors offices and hospitals, but even in retail stores. Bone densitometry provides a quantitative measurement of bone mineralization that can be used to predict the risk of osteoporotic fractures.